Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Holdings Lowered by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 47.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 184,117 shares of the company's stock after selling 168,241 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.22% of Syndax Pharmaceuticals worth $2,434,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $26,000. Virtus ETF Advisers LLC grew its holdings in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares in the last quarter. Cape Investment Advisory Inc. grew its holdings in Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after purchasing an additional 3,927 shares in the last quarter. KBC Group NV grew its holdings in Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after acquiring an additional 3,559 shares in the last quarter. Finally, Optimize Financial Inc acquired a new position in Syndax Pharmaceuticals during the 4th quarter worth $152,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Citigroup decreased their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Scotiabank lifted their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock traded down $0.96 during midday trading on Friday, reaching $9.85. 3,902,175 shares of the company were exchanged, compared to its average volume of 1,770,764. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $25.07. The company has a market cap of $847.56 million, a P/E ratio of -2.71 and a beta of 0.82. The company's 50 day moving average price is $11.83 and its two-hundred day moving average price is $13.80.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same quarter last year, the firm posted ($0.85) earnings per share. The firm's quarterly revenue was up 1900.0% compared to the same quarter last year. As a group, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).